since it would be categorically unwise to state that more good news was to come unless in fact that was the case i have to take this shareholder's letter as a positive ref the development of the osteogram...it is a huge mkt and if they can get the product more into the mainstream it obviously would have a significant impact on the numbers...all above my opinion only:
(PR NEWSWIRE) CompuMed, Inc. Releases Shareholder Letter
CompuMed, Inc. Releases Shareholder Letter
LOS ANGELES, Sept. 27 /PRNewswire/ -- CompuMed, Inc.
(OTC Bulletin Board: CMPD), a leading provider of computer based medical
diagnostics, today released the following letter to its shareholders.
Dear Shareholders,
I am writing to introduce myself and update you on CompuMed's progress.
As you all know, I was appointed President and Chief Executive Officer of
CompuMed on June 1, 2000. Since then we have made significant inroads into
further executing our business plan including the launch of OsteoGram(R), a
second-generation technology that enables a simple hand x-ray to be used to
precisely determine bone mineral density as an indicator of osteoporosis.
Today, physicians are paying close attention to the cost of providing services
and the added cost of equipment for diagnosis and treatment. OsteoGram(R),
our user-friendly and inexpensive bone densitometer software allows physicians
with access to an x-ray machine to perform bone density testing and diagnose
osteoporosis without incurring the high cost of adding additional
infrastructure and equipment.
OsteoGram(R) was made available for sale in June 2000. To date, we have
assembled and trained an eleven person sales force covering 24 states. We
will train an additional group of independent sales representatives and expand
our sales force as well as our area of coverage in the next three months. Our
highly experienced and motivated team has already commenced their proactive
selling activities. Early indications and preliminary feedback from the sales
force is positive.
In an effort to educate the medical community and promote the many
benefits of OsteoGram(R) we have begun presenting at key medical industry
trade events. We have attended the following events:
-- On June 16th we presented the benefits of OsteoGram(R) and described
the broad implications of the osteoporosis diagnosis kit in the
treatment of the disease at the World Congress on Osteoporosis 2000.
-- In August, CompuMed was invited and attended the 14th Annual Metabolic
Bone Disease Society of Colorado Conference on Osteoporosis Issues, a
premier educational conference on metabolic bone disease in the Rocky
Mountain region.
-- In early September, at the Federation of International Gynecology &
Obstetrics we had an option leader seminar and trained our second group
of independent sales representatives. At the seminar, option leaders
saw a demonstration of OsteoGram(R) and gave feedback on the system and
on their ability to integrate it into their practice.
-- On September 22nd we presented three abstracts at the Annual Meeting of
the American Society for Bone and Mineral Research held in Toronto,
Ontario. The abstracts presented evaluated hand x-ray methods for the
testing of bone mineral density.
In August, CompuMed established the CompuMed Scientific Advisory Board to
provide guidance and advice to the Company on its research and development
programs and the roll out of its OsteoGram(R) product to the medical
community. Dr. Stuart Silverman was appointed Chairman of the Scientific
Advisory Board. Dr. Silverman is a Clinical Professor of Medicine at the UCLA
School of Medicine. He is also the Medical Director of the OMC Clinical
Research Center in Beverly Hills, CA, a nationally recognized clinical
research center for osteoporosis and a member of CompuMed's Board of
Directors.
At the first meeting in Los Angeles on August 14, the board was provided
with new information about OsteoGram(R) and discussed the role of peripheral
measurement in the diagnosis, screening and treatment of osteoporosis;
creation of easier to use reporting of bone mineral density measurement using
OsteoGram(R); and, the clinical use of OsteoGram(R) in the diagnosis of
osteoporosis.
CompuMed is committed to its shareholders and to keeping them informed of
the progress we make at the Company. In an effort to ensure consistent
communications with our shareholders we will be issuing similar letters going
forward. Stay tuned for more good news.
Herbert S. Lightstone
President & CEO
Contact: Denise Roche of The Ruth Group Inc., 917-639-4109, for CompuMed,
Inc.
SOURCE CompuMed, Inc.
-0- 09/27/2000
/CONTACT: Denise Roche of The Ruth Group Inc., 917-639-4109, for
CompuMed, Inc./
(CMPD)
CO: CompuMed, Inc.
ST: California
IN: CPR BIO
SU:
*** end of story *** |
